Cabozantinib use in renal cell carcinoma.

• Autores: E. A. Neuwelt, S. Mathur, T.A. Johnson, Elizabeth R. Kessler, Daniel W. Bowles
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 53, Nº. 5, 2017, págs. 299-308
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In the last several years, many new drugs have been approved to treat metastatic renal cell carcinoma (RCC). Cabozantinib is a novel multikinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR), proto-oncogene tyrosine-protein kinase receptor Ret and other kinases that recently joined this impressive list of approved agents. Cabozantinib is an active agent in the preclinical and clinical setting, having recently demonstrated superiority over everolimus in a blinded, randomized phase III study of patients with progressive RCC after at least one prior line of antiangiogenic therapy. This agent’s toxicity profile is similar to those of other multikinase inhibitors approved to treat RCC. This review will explore cabozantinib's pharmacologic and safety profile and its preclinical and clinical activity in RCC.